Mar 28 |
Acrivon Therapeutics GAAP EPS of -$0.86
|
Mar 28 |
Acrivon Therapeutics: Q4 Earnings Insights
|
Mar 28 |
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
|
Mar 5 |
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
|
Mar 4 |
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
|
Feb 27 |
Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
|
Feb 8 |
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors
|
Feb 6 |
Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
|
Jan 4 |
Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
Jan 3 |
Acrivon Therapeutics appoints Jean-Marie Cuillerot as Chief Medical Officer
|